Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

Pharmacogenetics

Volumn 12, Issue 6, 2002, Pages 465-472

  Rau, Thomas ^a   Heide, Roland ^a   Bergmann, Klaus ^a   Wuttke, Henrike ^a   Werner, Ulrike ^a   Feifel, Nico ^a   Eschenhagen, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Beta adrenoceptor antagonist; Cytochrome P 450 CYP2D6; Metoprolol; Pharmacogenetics

Indexed keywords

ALPHA HYDROXYMETOPROLOL; BELOC ZOK; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; METOPROLOL TARTRATE; ALPHA-HYDROXYMETOPROLOL; DRUG DERIVATIVE; METOPROLOL; PRIMER DNA;

ADULT; AGED; ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; PHARMACOGENETICS; PRIORITY JOURNAL; BLOOD; CAUCASIAN; CHEMISTRY; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION; ENZYMOLOGY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; METABOLISM; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADRENERGIC BETA-ANTAGONISTS; CAUCASOID RACE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERTENSION; MALE; METOPROLOL; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SUPPORT, NON-U.S. GOV'T; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS;

EID: 0036667952     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200208000-00007     Document Type: Article

References (33)

1. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study
2. Long-term treatment with metoprolol after myocardial infarction: Effect on 3 year mortality and morbidity
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
4. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)
5. Oxidation phenotype - A major determinant of metoprolol metabolism and response
6. Metoprolol metabolism and debrisoquine oxidation polymorphism - Population and family studies
7. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
8. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
9. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
10. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing
11. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers
12. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
13. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
14. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications
15. A sensitive assay of metoprolol and its major metabolite alpha-hydroxy metoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detection
16. Analytical method validation: Bioavailability, bioequivalence, and pharmacokinetic studies
17. Nomenclature for human CYP2D6 alleles
18. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene
19. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: A role for the CYP2D6*35 allele in ultrarapid metabolism?
20. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
21. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene
22. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers
23. Enantioselective analysis of metoprolol in plasma using high-performance liquid chromatographic direct and indirect separations: Applications in pharmacokinetics
24. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers
25. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes
26. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol
27. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment
28. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension
29. Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects
30. Drug interaction between propafenone and metoprolol
31. Interaction of metoprolol and fluoxetine
32. Pharmacogenetic effect on the therapeutic safety of metoprolol: Association of CYP2D6 genotype and adverse drug reactions